Transitions lenses A.I CyberSecurity Scoring
23/01/2026
Access Monitoring Plan
Access Monitoring Plan
No incidents recorded for Transitions lenses in 2026.
No incidents recorded for Transitions lenses in 2026.
No incidents recorded for Transitions lenses in 2026.
Edwards Lifesciences (NYSE: EW), is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence and partnerships with clinicians and healthcare stakeholders, our employees are inspired by our patient-focused culture to deliver life-changing innovations to those who need them most. We thrive on discovery and expanding the boundaries of medical technology, serving patients in 100+ countries, with the help of our employees in areas including Clinical Affairs, Quality Engineering, Research & Development, Regulatory Affairs, Sales & Marketing, corporate functions and more. Contact Us We want to hear from you and engage in meaningful discussions. However, please note that we are not equipped to provide customer, candidate, or technical support through this platform. If you require assistance from those teams, please find their contact information here: https://www.edwards.com/aboutus/contactus If you’re a patient in need of medical advice, please contact your healthcare provider directly. We reserve the right to remove any comments that are off-topic, repetitive, or include hate speech, profanity, or offensive language. Additionally, we will not engage in discussions about competitor products, off-label use of Edwards products, or unsubstantiated/misleading claims that could cause harm. All Terms and Conditions of LinkedIn apply. For the Edwards Lifesciences privacy policy, visit https://www.edwards.com/legal/privacypolicy.
Boston Scientific transforms lives through innovative medical technologies that improve the health of patients around the world. As a global medical technology leader for more than 40 years, we advance science for life by providing a broad range of high-performance solutions that address unmet patient needs and reduce the cost of health care. Our portfolio of devices and therapies helps physicians diagnose and treat complex cardiovascular, respiratory, digestive, oncological, neurological and urological diseases and conditions. For more information, visit www.bostonscientific.com and connect with us on X, Instagram, and Facebook. At Boston Scientific, you will find purpose, a place to grow and opportunities to cultivate your passions. To search and apply for open positions, visit https://bostonscientific.eightfold.ai/careers. You may also review our social media guidelines at http://www.bostonscientific.com/social.
Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside its customers around the world, Stryker impacts more than 150 million patients annually. More information is available at stryker.com and careers.stryker.com. Facts: ● 2024 Sales: $22.6 billion ● Industry: Medical Instruments & Supplies ● Employees: 53,000 worldwide ● 44+ Manufacturing and R&D Locations Worldwide ● $1.5 billion spent on research and development in 2024 ● ~14,200 patents owned globally in 2024 ● Products sold in ~75 countries ● Fortune 500 Company ● 9 consecutive years as one a World's Best Workplace Stryker’s social media community guidelines: https://www.stryker.com/content/m/legal/social-media-community-guidelines/en/index.html Notice Regarding Employee Conduct on Facebook/LinkedIn Meta/LinkedIn does not permit employers to verify or validate “employees” in the (META: “Works at” LinkedIn: “Experience”) section of users’ profiles. Please be aware that the views expressed by individuals on their personal accounts and do not necessarily represent the views of our company. If you encounter any issues with a person claiming to be our employee, we recommend using the “Report Profile” feature. If you’d like to report concerns to our Ethics Hotline, you may do so at: https://app.convercent.com/en-us/LandingPage/b6bb4e84-9fcb-ea11-a974-000d3ab9f296
STERIS is a leading provider of infection prevention and other procedural products and services, focused primarily on healthcare, pharmaceutical and medical device Customers. MISSION WE HELP OUR CUSTOMERS CREATE A HEALTHIER AND SAFER WORLD by providing innovative healthcare and life science products and services around the globe. VISION We strive to be a GREAT COMPANY. We provide world-class products and services for our Customers, safe and rewarding work for our people, and superior returns for our Shareholders. • $5 Billion in revenue in FY24 • More than 17,000 Associates worldwide • Over 4,000 Customer-facing professionals • Listed on the New York Stock Exchange under the symbol “STE” To learn more, visit www.steris.com. Want to join the team? View and apply for open roles at careers.steris.com.
Olympus is passionate about creating customer-driven solutions for the medical industry. For more than 100 years, Olympus has focused on making people’s lives healthier, safer and more fulfilling by helping detect, prevent, and treat disease, furthering scientific research, and ensuring public safety. Olympus is headquartered in Tokyo, Japan, with more than 31,000 employees worldwide in nearly 40 countries and regions.
As a leading medical technology company, B. Braun protects and improves the health of people around the world. For more than 185 years, the family-owned company has been accelerating progress in health care with pioneering spirit and groundbreaking contributions. This innovative strength continues to be the foundation of B. Braun's success today—always with the goal of improving clinical outcomes, cost of care and patient benefits. More than 64,000 employees live Sharing Expertise worldwide, they make B. Braun a true partner that develops integrated solutions and sets new standards. By linking products, services and consulting, the company improves treatment processes and supports medical staff. In doing so, B. Braun always acts with future generations in mind, which is why responsibility for sustainable growth is embedded into all business processes. In 2024, the B. Braun Group generated sales of € 9.1 billion. Imprint: https://www.bbraun.com/en/imprint.html Privacy Policy: https://www.bbraun.com/en/privacy-policy.html
Smith+Nephew is a global medical technology company. We design and manufacture technology that takes the limits off living. We support healthcare professionals to return their patients to health and mobility, helping them to perform at their fullest potential. From our first employee and founder, T.J. Smith, to our team today, it’s our people who make Smith+Nephew a unique place. Yes, we love to innovate and develop exciting technologies, and we offer competitive salaries and progressive benefits. But it’s our culture - of Care, Collaboration and Courage - that really sets us apart. Through a spirit of ownership and can-do attitude, we work together to win.. We’re a company of people who care about each other, about our customers and their patients, and about our communities. Together, we fulfill our shared purpose of Life Unlimited. Please note: not all products referred to may be approved for use or available in all markets.
Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight and improve people’s lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Our more than 25,000 associates are enhancing the quality of life through innovative products, partnerships with Eye Care Professionals and programs that advance access to quality eye care. Learn more at www.alcon.com.
Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. We partner with customers across the globe to help them solve their most complex challenges, architecting solutions that bring the power of science to life. Our global teams are pioneering what’s next across Life Sciences, Diagnostics, Biotechnology and beyond. For more information, visit www.danaher.com.
Latest updates, reports, and threat intel affecting the global network.
This research identifies key actors and clarifies governance responsibilities within the complex transition to quantum-resistant...
In-depth review of the best camera glasses will guide you through the camera, video, and still images recording of this wearable gadget...
A growing number of enterprises in Australia are taking a centralized, cloud-based approach to cybersecurity amid rising threats,...
Ray-Ban models like the Aviator, Wayfarer, and Clubmaster have garnered iconic status in eyewear fashion, and their polarized lens glass...
Michael Kratsios served as chief tech officer under first Trump administration. Gail Slater advises JD Vance on economic policy.
The Tifosi Stash is a real pleasant surprise, as they perform amazingly well for cycling and also very good for trail running, with great fit, coverage/...
The glasses first had a slow, uneven transition from dark gray or brown to a translucent yellow-ish shade, making them more about function...
New global research offers insights for cyber teams as they adapt critical infrastructure defences for a rapidly evolving energy landscape.
We are EssilorLuxottica, a global leader in world-class vision care products, including iconic eyewear, advanced lens technology and cutting-edge digital...
Nginx Proxy Manager through 2.16.0 fails to restrict the advanced_config field to administrators, allowing non-admin users with manage permissions to inject arbitrary nginx directives. Attackers can inject malicious nginx configuration such as alias directives to serve arbitrary files or control routing for their assigned hosts.
Nginx Proxy Manager through 2.16.0 lacks rate-limiting on authentication endpoints, allowing unauthenticated attackers to make unlimited password guesses against any account. Attackers can brute-force login credentials via POST /api/tokens and subsequently guess TOTP codes via POST /api/tokens/2fa to gain full session access and administrative control.
httpdbg before 2.2.1 fails to validate URL schemes in recorded HTTP request URLs rendered as clickable links in the web interface. Attackers controlling traffic recorded by httpdbg can supply javascript: scheme URLs that execute malicious scripts in the application origin when clicked, allowing access to captured request and response data including headers and tokens.
Dozzle versions before 11.1.2 fail to sanitize container display names when building ZIP archive entry names in the log download endpoint. Attackers who can label containers can use path traversal sequences to write files outside the extraction directory when users download and extract logs.
A vulnerability has been found in Ziroom ZHOME A0101 1.0.1.0. This vulnerability affects unknown code of the file /api/ZRQos/set_online_client. The manipulation of the argument ip leads to command injection. It is possible to initiate the attack remotely. The exploit has been disclosed to the public and may be used. The vendor was contacted early about this disclosure but did not respond in any way.
curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'
Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.
Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.